Tadashi Ikegami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6805465/publications.pdf

Version: 2024-02-01

471509 434195 1,205 34 17 31 citations h-index g-index papers 34 34 34 1878 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Macâ€2â€binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C. Hepatology Communications, 2022, 6, 1855-1869.	4.3	3
2	Evaluation of the Risk of Clostridium difficile Infection Using a Serum Bile Acid Profile. Metabolites, 2022, 12, 331.	2.9	1
3	Realâ€world efficacy and safety of 12â€week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatology Research, 2021, 51, 51-61.	3.4	20
4	Western Diet Changes Gut Microbiota and Ameliorates Liver Injury in a Mouse Model with Human‣ike Bile Acid Composition. Hepatology Communications, 2021, 5, 2052-2067.	4.3	7
5	Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition. Journal of Lipid Research, 2020, 61, 54-69.	4.2	115
6	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. International Journal of Molecular Sciences, 2020, 21, 4939.	4.1	8
7	Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Acta Hepatologica Japonica, 2020, 61, 276-278.	0.1	2
8	Evaluation of 8â€week glecaprevir/pibrentasvir treatment in directâ€acting antiviralâ€naìve noncirrhotic HCV genotype 1 and 2infected patients in a realâ€world setting in Japan. Journal of Viral Hepatitis, 2019, 26, 1266-1275.	2.0	13
9	Circulating bile acid profiles in Japanese patients with NASH. GastroHep, 2019, 1, 302-310.	0.6	7
10	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. Hepatology Research, 2019, 49, 369-376.	3.4	9
11	Efficacy of directâ€acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. Hepatology Research, 2019, 49, 125-135.	3.4	15
12	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease. Hepatology Research, 2018, 48, 549-555.	3.4	19
13	Detection of Gut Dysbiosis due to Reduced Clostridium Subcluster XIVa Using the Fecal or Serum Bile Acid Profile. Inflammatory Bowel Diseases, 2018, 24, 1035-1044.	1.9	40
14	Reciprocal interactions between bile acids and gut microbiota in human liver diseases. Hepatology Research, 2018, 48, 15-27.	3.4	37
15	Efficacy and Safety of Glecaprevir/Pibrentasvir Combination Therapy in Genotype 1b Chronic Hepatitis C Patients with and without Cirrhosis Undergoing Hemodialysis. Acta Hepatologica Japonica, 2018, 59, 578-580.	0.1	1
16	Differences in the Serum $4\hat{l}^2$ -hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. Internal Medicine, 2018, 57, 1219-1227.	0.7	3
17	Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatology Research, 2017, 47, 1429-1437.	3.4	41
18	Effect of native vitamin D ₃ supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research, 2016, 46, 450-458.	3.4	15

#	Article	IF	CITATIONS
19	Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients. BMC Infectious Diseases, 2015, 15, 344.	2.9	10
20	Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. Biochemical and Biophysical Research Communications, 2014, 446, 736-740.	2.1	37
21	Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. Journal of Gastroenterology, 2012, 47, 1257-1266.	5.1	54
22	Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: An epidemiological survey of a large Japanese cohort. Hepatology Research, 2011, 41, 530-541.	3.4	17
23	Cholesterol 25-hydroxylation activity of CYP3A. Journal of Lipid Research, 2011, 52, 1509-1516.	4.2	99
24	Highly sensitive and specific analysis of sterol profiles in biological samples by HPLC–ESI–MS/MS. Journal of Steroid Biochemistry and Molecular Biology, 2010, 121, 556-564.	2.5	49
25	A case of the stenosis of the terminal ileum during taking NSAIDs. Progress of Digestive Endoscopy, 2010, 77, 108-109.	0.0	O
26	Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. Journal of Lipid Research, 2009, 50, 350-357.	4.2	165
27	Impact of determination of hepatitis B virus subgenotype and preâ€core/coreâ€promoter mutation for the prediction of acute exacerbation of asymptomatic carriers. Hepatology Research, 2009, 39, 341-345.	3.4	5
28	Transforming growth factorâ€Î² signaling and liver cancer stem cell. Hepatology Research, 2009, 39, 847-849.	3.4	11
29	Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatology Research, 2008, 38, 123-131.	3.4	93
30	Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS. Journal of Lipid Research, 2008, 49, 2063-2073.	4.2	140
31	Highly sensitive quantification of 7α-hydroxy-4-cholesten-3-one in human serum by LC-ESI-MS/MS. Journal of Lipid Research, 2007, 48, 458-464.	4.2	65
32	Liver Fibrosis: Possible Involvement of EMT. Cells Tissues Organs, 2007, 185, 213-221.	2.3	53
33	Alteration of intracellular taurine transporter expression in CCl ⟨sub⟩4⟨/sub⟩ â€induced liver disease. FASEB Journal, 2007, 21, A667.	0.5	O
34	Involvement of integrin-linked kinase in carbon tetrachloride–induced hepatic fibrosis in rats. Hepatology, 2006, 44, 612-622.	7.3	51